The rise of antimicrobial resistance represents a clear and present danger to efficient and effective healthcare delivery worldwide.
Part of Thorn Medical’s disease prevention, treatment and research and development strategy, Radley Pharma is a UK-based biopharmaceutical company focused on commercialising science into viable commercial products. This is leading to the development of products including next-generation antibiotics to destroy pathogenic, antimicrobial-resistant bacteria, including MRSA.
The company is also currently involved in bringing to market stem cell technology. Based on mesenchymal stem cell lines, this may lead to significant positive outcomes for a range of diseases including orthopaedic and neurodegenerative conditions.